Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin (incobotulinumtoxinA) [Short Flex Versus Long Flex] in Subjects With Cervical Dystonia With < 10 Weeks of Benefit From OnabotulinumtoxinA Treatment

X
Trial Profile

An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin (incobotulinumtoxinA) [Short Flex Versus Long Flex] in Subjects With Cervical Dystonia With < 10 Weeks of Benefit From OnabotulinumtoxinA Treatment

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Torticollis
  • Focus Therapeutic Use
  • Acronyms CD Flex
  • Sponsors Merz Pharma; Merz Pharmaceuticals
  • Most Recent Events

    • 26 Apr 2022 Results assessing the impact of 2 different injection schedules of incobotulinumtoxin A on patient-reported assessments in cervical dystonia (CD) presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 22 Sep 2021 Primary endpoint has been met. (Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Severity Subscale Score Based on Blinded Rater Assessment at Week 4 After the 8th Injection), as per Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top